February 15, 2017
The Ministry of Health, Labor and Welfare (MHLW) on February 14 ordered label revisions for Pfizer Japan’s psychoneurotic agent Atarax (hydroxyzine), and Chugai Pharmaceutical’s BRAF inhibitor Zelboraf (vemurafenib) for the addition of new adverse drug reactions (ADRs). In its notification...read more